researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Moderna has reported preliminary clinical ... and seems to offer improved protection. The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the ...

to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron subvariants BA.4 and BA.5. The US regulator has cleared a 30 µg booster dose of a new ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...